Early detection of bacterial airway infections in children with primary ciliary dyskinesia and cystic fibrosis by electronic nose.
- Conditions
- Primary ciliary dyskinesiaCystic fibrosis
- Registration Number
- NL-OMON26592
- Lead Sponsor
- Academic Medical Center and VU University Medical Center, Amsterdam.
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
Patients:
Children 0-17 years with cystic fibrosis or primary ciliary dyskinesia.
Exclusion Criteria
Patients:
Metabolic or inflammatory disorders.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Discrimination of CF-/PCD-patients with and without pulmonary infections;<br /><br>2. Discrimination of CF-/PCD-patients from healthy controls.
- Secondary Outcome Measures
Name Time Method Discrimination of different classes (aerobic, anaerobic, gram positive, gram negative strains), or types of bacteria responsible for the infection in vivo.<br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bacterial airway infection detection in primary ciliary dyskinesia and cystic fibrosis using electronic nose technology?
How does electronic nose detection compare to sputum culture in identifying bacterial infections in children with primary ciliary dyskinesia and cystic fibrosis?
What biomarkers are associated with early bacterial airway infection detection in primary ciliary dyskinesia and cystic fibrosis using electronic nose analysis?
Are there specific volatile organic compounds detected by electronic nose that correlate with Pseudomonas aeruginosa or Staphylococcus aureus infections in primary ciliary dyskinesia and cystic fibrosis patients?
What are the potential clinical applications of electronic nose technology in monitoring respiratory health for primary ciliary dyskinesia and cystic fibrosis beyond infection detection?